Mint Tax was founded in Vienna in 1960. By 2019, the company had approximately 80 employees and a broad client base in the areas of taxation, accounting, and payroll services. Over the previous decade, the company had experienced many successes and failures, including mergers, acquisitions, separations, firm structure changes, and financial losses. However, it had always managed to recover. Mint Tax was considering an expansion of its digital products, services, and internal processes and practices. The founder's daughter and current chief executive officer was motivated and had innovative ideas, but faced various challenges that prevented implementation of many of the company's ideas. To overcome these challenges, what steps should the chief executive officer and her team take to understand the company's strategic management patterns, identify and evaluate the company's capabilities, and develop solutions?

Mint Tax was founded in Vienna in 1960. By 2019, the company had approximately 80 employees and a broad client base in the areas of taxation, accounting, and payroll services. Over the previous decade, the company had experienced many successes and failures, including mergers, acquisitions, separations, firm structure changes, and financial losses. However, it had always managed to recover. Mint Tax was considering an expansion of its digital products, services, and internal processes and practices. The founder's daughter and current chief executive officer was motivated and had innovative ideas, but faced various challenges that prevented implementation of many of the company's ideas. To overcome these challenges, what steps should the chief executive officer and her team take to understand the company's strategic management patterns, identify and evaluate the company's capabilities, and develop solutions?

In 2018, President of the United States, Donald Trump, criticized the company Pfizer Inc. (Pfizer) for increasing drug prices—which had been a strategic move by Pfizer in response to industry-wide challenges. This announcement highlighted the complex dynamics of the pharmaceutical industry and the big challenges that innovative research and development (R&D)–intensive pharmaceutical companies faced. The entire pharmaceutical industry was being challenged by issues such as decreasing global average returns on investment and increased R&D costs. In addition, the company faced increased competition from companies from other industries and from emerging-market companies. Pfizer’s chief executive officer needed to determine whether or not these changes marked a turning point for the whole industry.

Case B complements Case A, describing pharmaceutical companies’ strategic responses—such as mega-mergers and acquisitions and specialization—to industry-wide global challenges and highlights strategic decisions by Pfizer’s chief executive officers between 2007 and 2018.

In 2018, President of the United States, Donald Trump, criticized the company Pfizer Inc. (Pfizer) for increasing drug prices-which had been a strategic move by Pfizer in response to industry-wide challenges. This announcement highlighted the complex dynamics of the pharmaceutical industry and the big challenges that innovative research and development (R&D)-intensive pharmaceutical companies faced. The entire pharmaceutical industry was being challenged by issues such as decreasing global average returns on investment and increased R&D costs. In addition, the company faced increased competition from companies from other industries and from emerging-market companies. Pfizer's chief executive officer needed to determine whether or not these changes marked a turning point for the whole industry.

Case B complements Case A (W19390), describing pharmaceutical companies' strategic responses-such as mega-mergers and acquisitions and specialization-to industry-wide global challenges and highlights strategic decisions by Pfizer's chief executive officers between 2007 and 2018.

In early 2015, the newly appointed country head of PharmaCorp's operating unit in Ukraine faced internal and external challenges in managing the global pharmaceutical company's operations in the crisis-ridden country. Since November 2013, Ukraine had undergone massive disruptions, including riots in Kiev, the annexation of Crimea by Russia, and a war in its easternmost region. Amid these economic and political turbulences, PharmaCorp Ukraine experienced plummeting sales, increased workload, amplified human resources issues, and decreased market share. Furthermore, the multinational corporation's internal routines became less effective in the context of the crisis. Although the regional headquarters in Lausanne, Switzerland, offered guidance and resources, inefficiencies in responding to local issues emerged during the crisis. Should PharmaCorp exit the market? Or should it stay in Ukraine and revise its local marketing strategy by offering more innovative products? Should it implement cost-saving measures? Should the business model be revised to gain more autonomy for its operations? The country head was scheduled to meet with representatives from the regional headquarters and needed to prepare a comprehensive strategy for improving the local situation.

In early 2015, the newly appointed country head of PharmaCorp’s operating unit in Ukraine faced internal and external challenges in managing the global pharmaceutical company’s operations in the crisis-ridden country. Since November 2013, Ukraine had undergone massive disruptions, including riots in Kiev, the annexation of Crimea by Russia, and a war in its easternmost region. Amid these economic and political turbulences, PharmaCorp Ukraine experienced plummeting sales, increased workload, amplified human resources issues, and decreased market share. Furthermore, the multinational corporation’s internal routines became less effective in the context of the crisis. Although the regional headquarters in Lausanne, Switzerland, offered guidance and resources, inefficiencies in responding to local issues emerged during the crisis. Should PharmaCorp exit the market? Or should it stay in Ukraine and revise its local marketing strategy by offering more innovative products? Should it implement cost-saving measures? Should the business model be revised to gain more autonomy for its operations? The country head was scheduled to meet with representatives from the regional headquarters and needed to prepare a comprehensive strategy for improving the local situation.